NASDAQ:ANGO AngioDynamics (ANGO) Stock Price, News & Analysis $8.45 -0.06 (-0.71%) Closing price 08/11/2025 04:00 PM EasternExtended Trading$8.41 -0.04 (-0.41%) As of 05:48 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About AngioDynamics Stock (NASDAQ:ANGO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get AngioDynamics alerts:Sign Up Key Stats Today's Range$8.38▼$8.5750-Day Range$8.40▼$11.1452-Week Range$5.83▼$13.50Volume365,971 shsAverage Volume826,000 shsMarket Capitalization$343.32 millionP/E RatioN/ADividend YieldN/APrice Target$19.00Consensus RatingBuy Company Overview AngioDynamics, Inc., a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium. Its thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit, indicated for extracorporeal circulatory support for periods of up to six hours including off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure. The company also offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters, and diagnostic and interventional guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits used during peripheral diagnostic and interventional procedures. In addition, it provides drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro-Access kits provides interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero MTA System includes solero microwave generator and the specially designed solero MW applicators. The company was founded in 1988 and is headquartered in Latham, New York. Read More AngioDynamics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks79th Percentile Overall ScoreANGO MarketRank™: AngioDynamics scored higher than 79% of companies evaluated by MarketBeat, and ranked 406th out of 1,853 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingAngioDynamics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAngioDynamics has only been the subject of 3 research reports in the past 90 days.Read more about AngioDynamics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for AngioDynamics are expected to grow in the coming year, from ($0.37) to ($0.26) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AngioDynamics is -10.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AngioDynamics is -10.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAngioDynamics has a P/B Ratio of 1.87. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about AngioDynamics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.43% of the outstanding shares of AngioDynamics have been sold short.Short Interest Ratio / Days to CoverAngioDynamics has a short interest ratio ("days to cover") of 4.8.Change versus previous monthShort interest in AngioDynamics has recently increased by 20.80%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAngioDynamics does not currently pay a dividend.Dividend GrowthAngioDynamics does not have a long track record of dividend growth. Sustainability and ESG4.2 / 5Environmental Score-0.99 Percentage of Shares Shorted7.43% of the outstanding shares of AngioDynamics have been sold short.Short Interest Ratio / Days to CoverAngioDynamics has a short interest ratio ("days to cover") of 4.8.Change versus previous monthShort interest in AngioDynamics has recently increased by 20.80%, indicating that investor sentiment is decreasing significantly. News and Social Media3.1 / 5News Sentiment0.64 News SentimentAngioDynamics has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for AngioDynamics this week, compared to 4 articles on an average week.Search Interest5 people have searched for ANGO on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, AngioDynamics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.40% of the stock of AngioDynamics is held by insiders.Percentage Held by Institutions89.43% of the stock of AngioDynamics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about AngioDynamics' insider trading history. Receive ANGO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AngioDynamics and its competitors with MarketBeat's FREE daily newsletter. Email Address ANGO Stock News HeadlinesAngioDynamics to Present at the Canaccord Genuity 45th Annual Growth ConferenceAugust 6, 2025 | businesswire.comRep. Debbie Wasserman Schultz Sells Off Shares of AngioDynamics, Inc. (NASDAQ:ANGO)August 4, 2025 | americanbankingnews.comMy shocking meeting in Washington, D.C.After a shocking discovery in D.C., Jeff Brown is revealing: President Trump’s “Project MAFA” Get a look inside Trump’s genius master plan to create a “new” gold standard, smash the U.S. debt, and kick off a Golden Century.August 12 at 2:00 AM | Brownstone Research (Ad)Rep. Debbie Wasserman Schultz Buys AngioDynamics, Inc. (NASDAQ:ANGO) SharesAugust 4, 2025 | americanbankingnews.comAngioDynamics Enrolls First Patient in AMBITION BTK Trial Advancing Treatment for Critical Limb IschemiaJuly 29, 2025 | finance.yahoo.comA Congress Member Sold Up To $30K In AngioDynamics Stock: Here's What You Need To KnowJuly 29, 2025 | benzinga.comAngioDynamics Stock (ANGO) Opinions on Congressional Stock SaleJuly 28, 2025 | quiverquant.comQAngioDynamics Announces Publication of PRESERVE Study of NanoKnife® System for Prostate Tissue Ablation in European UrologyJuly 24, 2025 | tmcnet.comSee More Headlines ANGO Stock Analysis - Frequently Asked Questions How have ANGO shares performed this year? AngioDynamics' stock was trading at $9.16 at the start of the year. Since then, ANGO shares have decreased by 7.8% and is now trading at $8.45. How were AngioDynamics' earnings last quarter? AngioDynamics, Inc. (NASDAQ:ANGO) issued its quarterly earnings data on Tuesday, July, 15th. The medical instruments supplier reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.12) by $0.09. The business's revenue for the quarter was up 13.0% compared to the same quarter last year. Read the conference call transcript. Does AngioDynamics have any subsidiaries? The following companies are subsidiaries of AngioDynamics: Eximo Medical Ltd., RadiaDyne LLC, Clinical Devices, Vortex Medical, Navilyst Medical Inc., FlowMedica, Oncovionic, and others. Who are AngioDynamics' major shareholders? AngioDynamics' top institutional shareholders include Geode Capital Management LLC (2.41%), Bastion Asset Management Inc. (2.36%), Pier Capital LLC (1.71%) and Connor Clark & Lunn Investment Management Ltd. (1.13%). Insiders that own company stock include James C Clemmer, James C Clemmer, Stephen A Trowbridge, Warren Nighan Jr and Dave Helsel. View institutional ownership trends. How do I buy shares of AngioDynamics? Shares of ANGO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of AngioDynamics own? Based on aggregate information from My MarketBeat watchlists, some other companies that AngioDynamics investors own include American Water Works (AWK), Waste Connections (WCN), Humana (HUM), Voyager Therapeutics (VYGR), The RMR Group (RMR), AU Optronics (AUOTY) and DiamondRock Hospitality (DRH). Company Calendar Last Earnings7/15/2025Today8/12/2025Next Earnings (Estimated)10/02/2025Fiscal Year End5/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED INSTRUMENTS Sub-IndustryHealth Care Equipment Current SymbolNASDAQ:ANGO CIK1275187 Webwww.angiodynamics.com Phone(518) 795-1400Fax518-795-1401Employees760Year Founded1988Price Target and Rating Average Price Target for AngioDynamics$19.00 High Price Target$24.00 Low Price Target$16.00 Potential Upside/Downside+124.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($0.83) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$33.99 million Net Margins-11.62% Pretax Margin-11.64% Return on Equity-3.20% Return on Assets-2.09% Debt Debt-to-Equity RatioN/A Current Ratio2.21 Quick Ratio1.40 Sales & Book Value Annual Sales$292.50 million Price / Sales1.17 Cash Flow$0.48 per share Price / Cash Flow17.47 Book Value$4.51 per share Price / Book1.87Miscellaneous Outstanding Shares40,630,000Free Float38,440,000Market Cap$343.32 million OptionableOptionable Beta0.67 Social Links Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:ANGO) was last updated on 8/12/2025 by MarketBeat.com Staff From Our PartnersWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredWhy Elon put $51 million into thisChris Rowe has made legendary calls—Tesla at $13, Nvidia at $40, Bitcoin under $1,000, Amazon at 12 cents. Now...True Market Insiders | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredSell these stocks now—what to buy insteadWall Street veteran Marc Chaikin—creator of the Power Gauge system—is warning that “smart money” is rapidly pu...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AngioDynamics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AngioDynamics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.